Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metastasis-Targeting Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TSPAN8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TSPAN8 LEL-Fc Fusion Protein (HEK293 Expressed) High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. Native Glycosylation. Ideal for LEL-specific antibody screening. |
View TSPAN8 Products |
| Gene Delivery | TSPAN8 Promise-ORF / Lentivirus Full-length human TSPAN8 ORF for stable cell line construction. Preserves native 4-transmembrane conformation for cell-based assays. |
View TSPAN8 Products |
| Benchmark Ab | Anti-TSPAN8 Recombinant Antibody Recombinant positive control derived from clinical-stage benchmark sequences. |
View TSPAN8 Products |
| Validator | TSPAN8 siRNA Set For target knockdown verification in high-throughput phenotypic assays. |
View TSPAN8 Products |
| Related Target A | CD151 Tetraspanin family member co-expressed with TSPAN8; crucial for specificity and selectivity counter-screening. |
View CD151 Products |
| Related Target B | EpCAM Frequently co-localized with TSPAN8 in tumor-initiating cell complexes, serving as a synergistic target for bispecifics. |
View EpCAM Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent binding of multi-pass membrane targets | Lentiviral transduction vectors available for stable overexpressing cell line generation, ensuring native 4-TM folding. |
| Off-target binding to homologous tetraspanins (e.g., CD9, CD81, CD151) | High-purity recombinant LEL domain proteins for family-wide selectivity panels. |
| Lack of standardized positive controls | Recombinant sequence-verified benchmark antibodies included in the catalog. |
| Assay noise from non-specific binding | Strictly endotoxin-controlled, HEK293-expressed proteins with >95% purity by SDS-PAGE. |
Live TSPAN8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TSPAN8 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific constructs. Because TSPAN8 is highly enriched on tumor-derived extracellular vesicles (EVs) and plays a key role in cancer metastasis, targeting this tetraspanin offers a unique therapeutic avenue for aggressive solid tumors, including pancreatic, colorectal, and gastric cancers. As first-generation therapies reach preclinical and early clinical milestones, the next wave of R&D is targeting highly selective epitope regions within the Large Extracellular Loop (LEL) to minimize off-target toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADC) | Biotech Startups, Academic Consortia | Pancreatic Cancer, Colorectal Cancer | Internalization Assay (Requires stable cell lines via Lentivirus and high-purity LEL-Fc proteins) |
| Bispecific Antibodies | Oncology-focused Biopharma | Gastric Cancer, Metastatic Solid Tumors | Heterodimer Validation (Requires cross-reactive targets like EpCAM and CD151) |
| CAR-T / Cell Therapy | Cellular Immunotherapy Developers | Gastrointestinal Malignancies | Flow Cytometry Screening (Requires stable target-expressing cell lines built with Lentiviral vectors) |